Scheduling, administration, biomarkers, and practical guidance.
Standard starting dose. Administer after 8-10 hour overnight fast. Wait 30-60 minutes before eating to allow B3-AR activation without insulin interference.
Higher dose range used in clinical and practitioner settings. Do not exceed 500 mcg/day. Efficacy above 250 mcg is not established in controlled trials.
Used in earlier clinical trials. Oral bioavailability is lower than subcutaneous. Higher GI side effect incidence. Not the standard route in current practice.
Used in the 2015 rabbit OA model with hyaluronic acid. Ultrasound-guided. No human intra-articular protocol exists. This is a research route, not a clinical one.
Followed by a 4-week rest period. The rest is precautionary; AOD-9604 does not suppress the HPTA or disrupt endocrine function. The rest period allows assessment of baseline metabolic status.
The fasting requirement is mechanistic, not optional. Insulin suppresses hormone-sensitive lipase and downregulates B3-AR expression. Morning dosing after overnight fast provides the optimal low-insulin environment.